Please use this identifier to cite or link to this item:
HPGF Biomedical Product:
Business Model & Strategy of GwoRei Biomedical Technology Company
Business Model Business Strategy,Biotechnology Growth Factor,Five Forces Analysis,SWOT,Value Chain,
|Publication Year :||2011|
Currently, the global biotechnology industry in various countries is actively promoting the economic revitalization of health care program reforms.This is creating new business opportunities and promoting the biotech industry as a key project.Taiwan’s biotech industry, being promoted by the government, has already constructed high quality clinical research labs, sound R&D, and has intellectual property protection amongst many other advantages. Because of this, Taiwan companies have excellent opportunities and conditions to partner with countries in Asia and ultimately become a multinational, international company.
However, even in these environmental conditions, the business strategy and business model are still the keys to success. From product development, to market development, to the profit model, to strategic planning on how to make innovative biotech products, must all be implemented in order to become sustainable and successful in the market.
In GwoRei’s case, its main product is the natural extraction of multiple blood growth factors and the investigation of internal resources and the external competitive environment. From each of its core products, it is important to look at the strategic planning, five forces analysis, value chain, and SWOT analysis to describe the advantages and disadvantages of the development. The study of the developmental process, to bring the products to market as soon as possible, to have return on the invested capital, and to extend the corporate life is the ultimate goal of the business.
|Appears in Collections:||商學組|
Files in This Item:
|2.05 MB||Adobe PDF|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.